跳转至内容
Merck
CN
  • HDR syndrome: a follow-up genotype-phenotype analysis of a de novo missense Thr272Ile mutation in exon 4 of GATA3.

HDR syndrome: a follow-up genotype-phenotype analysis of a de novo missense Thr272Ile mutation in exon 4 of GATA3.

Klinische Padiatrie (2012-12-04)
T S Gomes, L Gortner, G Dockter, D Leitner, R V Thakker, T Rohrer
摘要

Hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR) syndrome (MIM 146255) is a rare autosomal dominant disorder caused by mutations in the gene encoding GATA3, a dual zinc-finger transcription factor involved in vertebrate embryonic development. In this clinical case study we report on a follow-up of a phenotype associated with a GATA3 mutation. HDR syndrome was clinically diagnosed at age of 1.5 years in a boy with a de novo heterozygous missense (c.815C→T) mutation, Thr272Ile, in exon 4 of the GATA3 gene. Both parents were negative for Thr272Ile.At age of 17 months, the patient had a weight of 10.7, a body length of 78 cm, and a head circumference of 47.5 cm. By the age of 7 years, growth is age-appropriate, severe bilateral hearing loss (dB 60) was corrected by hearing aids. However, cognitive development (auditory sensory me-mory and language abilities) is at the lower ends of the test scores.In conclusion, a mildly impaired clinical course was achieved by the age of 7 years in a patient with HDR syndrome; this report adds to the body of data on genotype-phenotype analysis in HDR syndrome. ·

材料
产品编号
品牌
产品描述

Sigma-Aldrich
L -异亮氨酸, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L -异亮氨酸, reagent grade, ≥98% (HPLC)
SAFC
L -异亮氨酸
Sigma-Aldrich
L -异亮氨酸, BioUltra, ≥99.5% (NT)
Supelco
L -异亮氨酸, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L -异亮氨酸, 99%, FCC, FG
Supelco
L -异亮氨酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland